Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma
NCT07236528Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in mucosal melanoma (MM), sponsored by Nanjing Drum-Tower Hospital. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT07236528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07236528.